Table 1.

Patient characteristics (N=28)

Age in years, median (IQR)	64 (48–69·5)
ECOG Performance Status, N (%)
0	5 (18%)
1	22 (79%)
2	1 (3%)
Platinum-sensitive recurrence, N (%)	6 (21%)
Platinum-resistant recurrence (primary/secondary)*, N (%)	21 (75%; 2/19)
Platinum-refractory disease, N (%)	1 (4%)
Median number of prior systemic therapy regimens (IQR)	5 (2·5–5)
Median number of prior cytotoxic chemotherapeutic agents (IQR)	3 (2–4·5)
Prior cytotoxic chemotherapy, N (%)	28 (100%)
Prior radiotherapy, N (%)	2 (7%)
Prior PARP inhibitor(s), N (%)	9 (32%)**
Prior bevacizumab, N (%)	13 (46%)
Prior immune checkpoint inhibitor or vaccine, N (%)	7 (25%)
Baseline CA125
Normal (1·9–16·3 units/mL), N (%)	1 (4%)
Abnormal (> 16·3 units/mL), N (%)	27 (96%)

All but one patient had results on germline BRCA mutation evaluation by commercial testing prior to enrollment. The single patient had negative family history of hereditary breast and ovarian cancer syndrome and her germline BRCA mutation testing by BROCA-HR later was negative.

^*Patients were categorized as primary platinum-resistant disease (progression < 6 months after completing first-line platinum therapy) or secondary platinum-resistant (progression ≥ 6 months after first-line platinum therapy but progressed < 6 months after second or last platinum-based therapy).

^**Five were treated with olaparib on one of several NCI olaparib combination trials. Four patients received PARP inhibitors (olaparib, veliparib or rucaparib) in other clinical trial settings.

Abbreviations: ECOG=Eastern Cooperative Oncology Group.